MARK LOWDELL: Hello,
I'm Mark Lowdell.
I'm the Director of Cell
Therapy here at the Royal Free
Hospital & UCL Medical School.
And today I'm going to talk to you
about the field of cell and tissue
therapies, how they're
regulated, and the impact
that regulation has on the ethics.
So I'm a Cell Therapist.
I'm not a doctor here
that treats cells.
I'm a scientist that uses human
cells and tissues to make medicines
for tissue engineering,
regenerative medicine, and treating
cancer and immune deficiencies.
Now these types of
medicines are called
Advance Therapy Medicinal Products.
It's a clumsy term,
and it was defined
really in the first directive of
2001, 83, the Medicines Directive.
And they consist of gene
therapies, somatic cell therapies,
and tissue engineered
products for the purposes
of regenerative medicine.
Here are some examples:
In the lower screen
there you can see
a decellularized human
trachea that we were using
to rebuild a trachea in a child.
On the right of that there
is a bioengineered nose made
out of a biocompatible material.
On the right hand side, a
photograph from a different group
using a similar sort of bio materials
to produce an ear structure.